Advertisement
AXSM vs BBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and BBIO is a Hold.
AXSM sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for AXSM moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXSM as a result. In 52 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for AXSM turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 35 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AXSM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
AXSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (97.972) is slightly higher than the industry average of (2.978). P/E Ratio (-41.549) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (13.908) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BBIO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BBIO turned positive on October 01, 2026. Looking at past instances where BBIO's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BBIO's RSI Oscillator exited the oversold zone, 15 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BBIO as a result. In 80 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +6.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in 248 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for BBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for BBIO entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.281) is normal, around the industry mean (2.978). P/E Ratio (-19.084) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AXSM | BBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 38 | 75 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 16 | 24 | |
SEASONALITY SCORE 1..100 | 22 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BBIO's Valuation (7) in the null industry is significantly better than the same rating for AXSM (94) in the Pharmaceuticals Other industry. This means that BBIO’s stock grew significantly faster than AXSM’s over the last 12 months.
AXSM's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for BBIO (75) in the null industry. This means that AXSM’s stock grew somewhat faster than BBIO’s over the last 12 months.
AXSM's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as BBIO (100) in the null industry. This means that AXSM’s stock grew similarly to BBIO’s over the last 12 months.
AXSM's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as BBIO (50) in the null industry. This means that AXSM’s stock grew similarly to BBIO’s over the last 12 months.
AXSM's P/E Growth Rating (16) in the Pharmaceuticals Other industry is in the same range as BBIO (24) in the null industry. This means that AXSM’s stock grew similarly to BBIO’s over the last 12 months.
| AXSM | BBIO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 87% |
| Advances ODDS (%) | N/A | 5 days ago 82% |
| Declines ODDS (%) | 1 day ago 77% | 12 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 78% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXSM’s FA Score shows that 1 FA rating(s) are green while BBIO’s FA Score has 2 green FA rating(s).
- AXSM’s FA Score: 1 green, 4 red.
- BBIO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXSM’s TA Score shows that 3 TA indicator(s) are bullish while BBIO’s TA Score has 5 bullish TA indicator(s).
- AXSM’s TA Score: 3 bullish, 5 bearish.
- BBIO’s TA Score: 5 bullish, 4 bearish.
Price Growth
AXSM (@Biotechnology) experienced а -6.14% price change this week, while BBIO (@Biotechnology) price change was +3.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.
Reported Earning Dates
AXSM is expected to report earnings on Nov 02, 2026.
BBIO is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AXSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with CYTK. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To AXSM | 1D Price Change % | ||
|---|---|---|---|---|
| AXSM | 100% | -0.85% | ||
| CYTK - AXSM | 41% Loosely correlated | +1.13% | ||
| PHVS - AXSM | 40% Loosely correlated | +7.32% | ||
| MIRM - AXSM | 38% Loosely correlated | +2.62% | ||
| BBIO - AXSM | 36% Loosely correlated | +2.33% | ||
| RYTM - AXSM | 36% Loosely correlated | +2.39% | ||
More | ||||